VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults
Status:
Terminated
Trial end date:
2019-01-14
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a
novel mechanism of action in immunocompromised adults with invasive aspergillosis.
Phase:
Phase 2
Details
Lead Sponsor:
Vical
Treatments:
Amphotericin B Isavuconazole Liposomal amphotericin B VL-2397 Voriconazole